Table 5. [Recommended Surveillance for Individuals with EPM1]. - GeneReviews®

System/Concern	Evaluation	Frequency
Myoclonus	Severity of myoclonus using UMRS	At least annually
Seizures	Seizure type & frequency
Cerebellar involvement	Clinical eval	Per symptom progression
Dysarthria	Need for alternative communication method or speech therapy
Dysphagia	Assess aspiration risk & feeding methods
Weight / Nutritional status	Monitor BMI. Consult a nutritionist High-calorie supplementation
Activities of daily living	Clinically to evaluate rehab plan	At least annually
School performance	Interview
Cognitive/Psychiatric	Evaluate mood, signs of psychosis, & cognitive complaints to identify need for pharmacologic & psychotherapeutic interventions.	Per symptom progression & development of psychiatric symptoms
Family support & resources	Interview	Annually

From: Progressive Myoclonic Epilepsy Type 1

GeneReviews^® [Internet].

Adam MP, Feldman J, Mirzaa GM, et al., editors.

Seattle (WA): University of Washington, Seattle; 1993-2024.

GeneReviews® chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (http://www.genereviews.org/) and copyright (© 1993-2024 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the GeneReviews® Copyright Notice and Usage Disclaimer. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.

For more information, see the GeneReviews® Copyright Notice and Usage Disclaimer.

For questions regarding permissions or whether a specified use is allowed, contact: ude.wu@tssamda.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.